Intensified Rituximab Induction Followed By Rituximab Maintenance For Low Grade B Cell Lymphoma: A Multicenter, Phase II Study

被引：0
|
作者：
Yamada, Kyouhei
Sawamura, Mario
Shimomura, Takeshi
Takeuchi, Makoto
Hanada, Shuichi
Komeno, Takuya
Hidaka, Michihiro
Yano, Takahiro
Kitano, Kiyoshi
Yoshida, Isao
Inoue, Nobumasa
Horibe, Keizo
Tomoyuki, Watanabe
Sunami, Kazutaka
Nagai, Hirokazu
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.1797.1797
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1797
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase II study of intensified rituximab induction and maintenance for low grade B cell lymphoma
    Nagai, Hirokazu
    Shimomura, Takeshi
    Takeuchi, Makoto
    Hanada, Shuichi
    Komeno, Takuya
    Sunami, Kazutaka
    Hidaka, Michihiro
    Yano, Takahiro
    Kitano, Kiyoshi
    Yoshida, Isao
    Inoue, Nobumasa
    Saito, Akiko
    Horibe, Keizo
    Motitani, Suzuko
    Ichihara, Shu
    Watanabe, Tomoyuki b
    Sawamura, Morio
    LEUKEMIA & LYMPHOMA, 2017, 58 (12) : 2845 - 2851
  • [2] Rituximab Maintenance Therapy in Diffuse Large B-Cell Lymphoma in a Multicenter Prospective Randomised Phase II Study
    Witzens-Harig, Mathias
    Benner, Axel
    Rieger, Michael
    McClanahan, Fabienne
    Hensel, Manfred
    Neben, Kai
    Dreger, Peter
    Lengfelder, Eva
    Schmidt-Wolf, Ingo
    Kraemer, Alwin
    Ho, Anthony D.
    BLOOD, 2011, 118 (21) : 1580 - 1581
  • [3] Rituximab maintenance therapy in diffuse large B-cell lymphoma in a multicenter prospective randomised phase II study
    Witzens-Harig, M.
    Benner, A.
    Rieger, M.
    McClanahan, F.
    Hensel, M.
    Neben, K.
    Dreger, P.
    Lengfelder, E.
    Schmidt-Wolf, I
    Kraemer, A.
    Ho, A. D.
    ONKOLOGIE, 2012, 35 : 86 - 86
  • [4] RITUXIMAB MAINTENANCE THERAPY IN DIFFUSE LARGE B-CELL LYMPHOMA IN A MULTICENTER PROSPECTIVE RANDOMISED PHASE II STUDY
    Witzens-Harig, M.
    Benner, A.
    Rieger, M.
    McClanahan, F.
    Hensel, M.
    Neben, K.
    Dreger, P.
    Lengfelder, E.
    Schmidt-Wolf, I.
    Kraemer, A.
    Ho, A.
    HAEMATOLOGICA, 2012, 97 : 93 - 94
  • [5] Increased Dose Rituximab Followed by Maintenance Rituximab As Initial Therapy for Indolent B Cell Lymphomas: A Phase II Trial
    Barnes, Jeffrey A.
    Stevenson, Kristen
    Hochberg, Ephraim P.
    Takvorian, Tak
    Fisher, David C.
    LaCasce, Ann
    Brown, Jennifer R.
    Mahindra, Anuj K.
    Neuberg, Donna
    Abramson, Jeremy S.
    BLOOD, 2011, 118 (21) : 1587 - 1588
  • [6] Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma
    Craig, Michael
    Hanna, Wahid T.
    Cabanillas, Fernando
    Chen, Chien-Shing
    Esseltine, Dixie-Lee
    Neuwirth, Rachel
    O'Connor, Owen A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 166 (06) : 920 - 928
  • [7] Initial Results of a Phase II Study of Sequential Chemotherapy and Lenalidomide Followed By Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma
    Kumar, Anita
    Zelenetz, Andrew D.
    Batlevi, Connie Lee
    Caron, Philip
    Dogan, Ahmet
    Drullinsky, Pamela
    Gerecitano, John
    Hamilton, Audrey
    Hamlin, Paul A.
    Laraque, Leana
    Matasar, Matthew J.
    McCall, Susan Jennifer
    Moskowitz, Alison J.
    Moskowitz, Craig H.
    Owens, Colette
    Pichardo, Janine
    Schoder, Heiko
    Sigler, Allison
    Straus, David J.
    Younes, Anas
    BLOOD, 2018, 132
  • [8] Phase II study of Rituximab in combination with Fludarabine in patients (pts) with low-grade or follicular B-cell lymphoma.
    Czuczman, MS
    Fallon, A
    Scarpace, A
    Stewart, C
    Bernstein, ZP
    McCarthy, P
    Skipper, M
    Brown, K
    Miller, K
    Wentling, D
    Rock, MK
    Benyunes, M
    Grillo-Lopez, A
    Bernstein, SH
    BLOOD, 2000, 96 (11) : 729A - 729A
  • [9] Rituximab plus CHOP followed by maintenance rituximab as initial therapy for aggressive non-Hodgkin's lymphoma (NHL); Initial results of induction therapy, including rituximab pharmacokinetics, in a phase II study.
    Huang, JE
    Saleh, A
    Lee, JT
    Langmuir, V
    Zhang, F
    Hainsworth, J
    BLOOD, 2004, 104 (11) : 238B - 238B
  • [10] Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma
    Tobinai, K
    Igarashi, T
    Itoh, K
    Kobayashi, Y
    Taniwaki, M
    Ogura, A
    Kinoshita, T
    Hotta, T
    Aikawa, K
    Tsushita, K
    Hiraoka, A
    Matsuno, Y
    Nakamura, S
    Morio, S
    Ohashi, Y
    ANNALS OF ONCOLOGY, 2004, 15 (05) : 821 - 830
12345